---
layout: post
title: "Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers; Guidance for Industry; Availability"
date: 2026-02-04 21:37:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-22427
original_published: 2025-12-10 00:00:00 +0000
significance: 8.00
---

# Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers; Guidance for Industry; Availability

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 10, 2025 00:00 UTC
**Document Number:** 2025-22427

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers." The guidance addresses questions that manufacturers, packers, distributors, and their representatives (firms) may have when developing FDA-regulated promotional labeling and advertisements (promotional communications) for prescription reference products, biosimilar products, and interchangeable biosimilar products licensed under the Public Health Service Act (PHS Act). This guidance finalizes the revised draft guidance of the same title issued on April 25, 2024.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/10/2025-22427/promotional-labeling-and-advertising-considerations-for-prescription-biological-reference-products)
- API: https://www.federalregister.gov/api/v1/documents/2025-22427

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
